Zambon has received initial approval from the Italian regulatory authorities for its new oral asthma treatment Summair (broxoterol). This is the first market to grant approval to the drug. However, the beta agonist has been classed as a non-reimbursable drug by the Italian authorities, and the company is unsure whether or not it will actually bring it to market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze